The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| RAPT | +68.75% | -87.08% | -33.57% | -71% |
| S&P | +17.35% | +108.64% | +15.84% | +125% |
Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA.
The company reported great results from an early-stage study of its experimental atopic dermatitis drug.
Incredibly, they're almost all health stocks, including 7 biotechs, an eye surgery platform, and a medical device company.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.23M | 25.2% |
| Market Cap | $132.29M | 24.6% |
| Market Cap / Employee | $2.17M | 0.0% |
| Employees | 61 | 0.0% |
| Net Income | -$17.64M | 36.2% |
| EBITDA | -$19.31M | 33.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $41.89M | 13.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.96M | -69.6% |
| Short Term Debt | $2.21M | -14.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -69.69% | -0.5% |
| Return On Invested Capital | -53.18% | -1.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$11.31M | 59.8% |
| Operating Free Cash Flow | -$11.27M | 60.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.73 | 1.10 | 0.91 | 0.74 | -8.26% |
| Price to Tangible Book Value | 5.14 | 4.62 | 6.78 | 0.74 | -88.53% |
| Enterprise Value to EBITDA | 0.75 | 2.95 | -4.59 | -2.58 | 693.94% |
| Return on Equity | -80.1% | -77.1% | -75.6% | -77.8% | -0.18% |
| Total Debt | $5.12M | $4.49M | $3.84M | $3.16M | -44.75% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
